Viral Disease Update: Editorial

Current Problems in Dermatology

Volumn 11, Issue 2, 1999, Pages 37-70

  Severson, Jessica L ^a,b,c   Tyring, Stephen K ^a,d,e,f,g  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF NORTH DAKOTA   (United States)

^c Univ of N Dakota Sch of Medicine   (United States)

^d INDIANA STATE UNIVERSITY   (United States)

^e ABILENE CHRISTIAN UNIVERSITY   (United States)

^f TEXAS TECH UNIVERSITY   (United States)

^g Texas Tech University ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; FAMCICLOVIR; IMIQUIMOD; PENCICLOVIR; PODOPHYLLOTOXIN; VALACICLOVIR;

CHICKENPOX; HERPES VIRUS; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOGENESIS; REVIEW; SERODIAGNOSIS; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0032818179     PISSN: 10400486     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1040-0486(99)90007-8     Document Type: Review

References (204)

1. Spruance S. Cold sores: a new understanding of their pathophysiology and the need for a new treatment. Virus Life 1996: June 7-10.
2. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
3. Warren KG, Brown SM, Wroblewska Z, Gilden D, Koprowski H, Subak-Shaupe J. Isolation of latent herpes simplex virus from the superior cervical and vagus ganglia of human beings. N Engl J Med 1978;298:1068-9.
4. Tyring SK, Sadovsky R. Management of herpesvirus infections. Am Fam Physician 1996;2:1-24.
5. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
6. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex infection. N Engl J Med 1987;316:1444-9.
7. Thandi A, Tyring S. Newer aspects of herpesvirus infections. Curr Opin Dermatol 1997;4:42-50.
8. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121:847-54.
9. Whitley RJ, Roizman B. Herpes simplex viruses. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical virology. Edinburgh: Churchill Livingstone; 1997. p 375-92.
10. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995;333:770-5.
11. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 1989;110:882-7.
12. Wald A. Genital HSV2 shedding in women with HSV2 antibodies but without a history of genital herpes. Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sept 15-18; New Orleans, Louisiana. New Orleans: The Conference; 1996.
13. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. J Clin Invest 1997;99:1092-7.
14. Bryson Y, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garrattyy E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993;167:942-6.
15. Pannuti C, Finck M, Grimbaun R, et al. Asymptomatic perianal shedding of herpes simplex virus in patients with acquired immunofeficiency syndrome. Arch Dermatol 1997; 133:180-3.
16. Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995;123:845-7.
17. Weinberg JM, Mysliwiec A, Turiansky GW, Redfield R, James WD. Viral folliculitis. Arch Dermatol 1997;133:983-6.
18. Donahue SP, Khoury JM, Kowalski RP. Common ocular infections. Drugs 1996;52:526-39.
19. Bale JF. Viral encephalitis. Med Clin North Am 1993;77:25-39.
20. Stamm W, Handsfield H, Rompalo A, Ashley R, Roberts P, Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988;260:1429-33.
21. O'Farrell N, Tovey S. High cumulative incidence of genital herpes amongst HIV-1 seropositive heterosexuals in south London. Int J STD AIDS 1994;5:415-8.
22. Wassertheit IN. Epidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992;29:61-77.
23. Holmberg S, Stewart JA, Gerber AR. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 1988;259:1048-50.
24. Heng MCY, Heng SY. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus 1. Lancet 1994;343:255-8.
25. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337: 509-15.
26. Maccato M. Herpes in pregnancy. Clin Obstet Gynecol 1993;36:869-77.
27. Hyde SR, Giacoia GP. Congenital herpes infection: placental and umbilical cord findings. Obstet Gynecol 1993;81: 852-5.
28. Cohen PR. Tests for detecting herpes simplex virus and varicella-zoster virus infections. Dermatol Clin 1994;12:51-65.
29. Coleman R, Pereira L, Bailey P, Tatsuno M. Detection of herpes simplex virus type specific antibodies by enzyme-linked immunosorbent assay. J Clin Microbiol 1983;18:287-91.
30. Lee F, Coleman R, Pereira L, Bailey P. Detection of herpes simplex virus type-2-specific antibody with gylcoprotein G. J Clin Microbiol 1985;22:641-4.
31. Reference deleted in press.
32. Weller S, Blum MR, Doucette M. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
33. Vere Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 1989;33:223-9.
34. Vere Hodge RA, Cheng Y-C. The mode of action of penciclovir. Antiviral Chem Chemother 1993;4:13-24.
35. Vere Hodge RA, Darlison SJ, Earnshaw DL, Readshaw SA. Use of isotopically chiral ((4c-13C))penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2-infected cells and by HSV-1-encoded thymidine kinase. Chirality 1993a;5:583-8.
36. Vere Hodge RA, Darlison SJ, Readshaw SA. Use ofisotopically chiral ((4c-13C))famciclovir and 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract. Chirality 1993b;5:577-82.
37. Pue MA, Pratt SK, Fairless AJ. Linear pharmacokinetics of penciclovir following oral administration of single oral doses of famciclovir 125, 250, 500, and 750 mg to healthy volunteers. J Antimicrobiol Chemother 1994;33:119-27.
38. Vere Hodge RA, Sutton D, Boyd M, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for antiherpesvirus agent BRL 39123 ((9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir)). Antimicrob Agents Chemother 1989;33:1765-73.
39. Reference deleted in press.
40. Earnshaw DL, Bacon TH, Darlison SJ, Emunds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36:2747-57.
41. Reference deleted in press.
42. Vere Hodge RA. Famciclovir and penciclovir: the mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993;4:67-84.
43. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994;38:2454-7.
44. Raborn GW, McGaw WT, Grace M, Tyrell LD, Samuels SM. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. J Am Dent Assoc 1987; 115:38-42.
45. Spruance SL, Stewart JCB, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990;161: 185-90.
46. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. Ann Intern Med 1993;118:268-72.
47. Van Vloten WA, Swart RNJ, Pot FJ. Topical acyclovir therapy in pateints with recurrent orofacial herpes simplex infections. Antimicrob Chenother 1983;12:89-93.
48. Shaw M, King MS, Best JM. Failure of acyclovir cream in treatment of recurrent herpes labialis. BMJ 1985;291:7-9.
49. Raborn GW, McGaw WT, Grace M, Percy J, Samuels S. Herpes labialis treatment with acyclovir 5% modified aqueous cream: a double-blind randomized trial. Oral Surg Oral Med Oral Pathol 1989;67:676-9.
50. Fiddian A, Yeo JM, Clark AE. Treatment of herpes labialis. J Infect 1983;6:41-7.
51. Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. JAMA 1997;277:1374-9.
52. Raborn GW. Penciclovir cream for recurrent herpes simplex labialis: an effective new treatment. Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996 Sept 16; New Orleans, Louisiana. New Orleans: The Conference; 1996.
53. Shafran SD, Sacks SL, Aoki FY. Topical undecylenic acid for herpes simplex labialis: a multicenter, placebo-controlled trial. J Infect Dis 1997;176:78-83.
54. Habbema L, De Boulle K, Roders GA, Katz DH. n-Docosanol 10% cream in the treatment of recurrent herpes labialis: a randomised, double-blind, placebo-controlled study. Acta Derm Venereol (Stockh) 1996;76:479-81.
55. Bryson YJ, Dillon M, Lovett, M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. N Engl J Med 1983;308:916-21.
56. Goldberg LH, Kaufman R, Kurrz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir. Arch Dermatol 1993;129:582-7.
57. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
58. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol 1996;87:69-73.
59. Randolph A, Hartshorn R, Washington A. Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet Gynecol 1996;88:603-10.
60. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, dose ranging trial of peroral valacyclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996;156:1729-35.
61. Leone P, Trottier S, Miller J. A comparison of oral valaciclovir 500 mg twice daily for three or five days in the treatment of recurrent genital herpes [poster presentation]. Proceedings of the International Congress on Infectious Diseases; 1998 May 15-19; Boston, Massachusetts. Boston: The Congress; 1998.
62. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valacyclovir versus acyclovir in the treatment of first-episode genital herpes infection. Sex Transm Dis 1997;24: 481-6.
63. Tyring SK, Douglas JM, Corey LC, Spruance SL, Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol 1998; 134:185-91.
64. Tyring SK. Once daily valacyclovir for suppression of genital herpes - results from a large, international controlled study [poster 295]. Proceedings of the 55th annual meeting of the American Academy of Dermatology; 1997 Mar 21-26; San Francisco, California. San Francisco: The Academy; 1997.
65. Tyring S, Price M, Grant D. Impact of suppressive antiviral therapy on the health-related quality of life of patients with recurrent genital herpes infection [poster presentation]. Proceedings of the International Congress on Infectious Diseases; 1998 May 15-18; Boston, Massachusetts. Boston: The Congress; 1998.
66. Lawrence A, Bell A. Valaciclovir for prevention of recurrent herpes virus infection in HIV-infected individuals-a double-blind controlled trial [poster presentation]. Proceedings of the 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25-28; Lausanne, Switzerland. Lausanne: The Congress; 1997.
67. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. JAMA 1996;276:44-9.
68. Sacks S. Famciclovir (FCV) for suppression of asymptomatic (ASx) and symptomatic (Sx) recurrent genital herpes (RGH) shedding: a randomized, double-blind, double-dummy, parallel-group, placebo-controlled trial. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997; Toronto, Ontario, Canada. Toronto: The Conference; 1997.
69. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. Arch Intern Med 1997;157:343-9.
70. Diaz-Mitoma F, Sibbald RG, Shafran SD. Famciclovir in suppression of recurrent genital herpes: results of a multinational study. Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sept 15-18, San Diego, California. San Diego: The Conference; 1996.
71. Tyring S, Diaz-Mitoma F, Locke L, Young C. Famciclovir for long-term suppression of recurrent genital herpes: a meta-analysis. Proceedings of the 8th International Congress on Infectious Diseases; 1998 May 15-18; Boston, Massachusetts. Boston: The Congress; 1998.
72. Locke L, Young C, Saltzman R. Famciclovir safety experience in long-term treatment and in immunocompromised patients [abstract]. Proceedings ot the 8th International Congress on Infectious Diseases; 1998 May 15-18; Boston, Massachusetts. Boston: The Congress; 1998.
73. Schacker T, Hu H-I, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. Ann Intern Med 1998;128:21-8.
74. Frechette G, Romanowsi B. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients. Proceedings of the 6th Annual Canadian Conference on HIV/AIDS Research; 1997 May 22-25; Ottawa, Ontario, Canada. Ottawa: The Conference; 1997.
75. Reyes M, Graber J, Reeves W. Acyclovir resistant HSV: preliminary results from a national surveillance system [abstract]. Proceedings of the International Conference on Emerging Infectious Diseases; 1998 Mar 8-11; Atlanta, Georgia. Atlanta: The Conference; 1998.
76. Xiong X, Smith JL. Effect of incorporation of cidofovir into DNA by cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997;41:594-5.
77. Lalezari J, Schaacker T, Feinberg J, Gathe J. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997;176:892-8.
78. Sacks S, Shafran S, Diaz-Mitoma F. A randomized, double-blind, placebo-controlled study of cidofovir gel for recurrent genital herpes infection. Proceedings of the 55th annual meeting of the American Academy of Dermatology; 1997 Mar 21-26; San Francisco, California. San Francisco: The Academy; 1997.
79. Terry B, Cianci C, Hagen M. Inhibition of herpes simplex virus type I DNA polymerase by [1R(1a,2B,3a)]-9-[2,3-bis(hydroxymethly)cyclobutyl] guanine. Mol Pharmacol 1991;40:591-6.
80. Bisacchi G, Braitman A, Cianci C. Synthesis and antiviral activity of enantiomeric forms of cyclobutyl nucleoside analogues. J Med Chem 1991;34:1415-21.
81. Braitman A, Swerdel M, Olsen S. Evaluation of SQ 34.514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice. Antimicrob Agents Chemother 1991;35: 1464-8.
82. Petty B, Wachsman M, Jordan M. Sequential ascending multiple-dose safety and pharmacokinetic study of oral lobucavir (BMS-180194) in asymptomatic volunteers seropositive for HIV and CMV [abstract 133]. Antiviral Res 1995; 26:A296.
83. Wilber R, Buffington D, Tyring S, Weinstein M, Leonard G. Efficacy and safety of oral lobucavir (LBV) in patients with recurrent genital herpes. Wallingford (CT): Bristol-Myers Squibb; 1998.
84. Langenberg AGM, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and immunogenicity. Ann Intern Med 1995;122:889-98.
85. Corey L, Langenberg AGM, Ashley R, et al. Two double-blind, placebo-controlled trials of a vaccine containing recombinant gD2 and gB2 antigens in MF59 adjuvant for the prevention of genital HSV-2 acquisition. Proceedings of the 37th annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sept 29-Oct 1; Toronto, Ontario, Canada. Toronto: The Conference; 1997.
86. Straus SE, Corey L, Burke RL, et ai. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994;343:1460-3.
87. Preblud S, Orenstein W, Bart K. Varicella: clinical manifestations, epidemiology, and health impact in children. Pediatr Infect Dis J 1984;3:505-9.
88. Wallace MR, Chamberlin CJ, Zerboni L, et al. Reliability of a history of previous varicella infection in adults. JAMA 1997;278:1520-2.
89. Donahue J, Choo P, Manson J, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9.
90. Straus S, Ostrove J, Inchauspe G. Varicella-zoster virus infections - biology, natural history, treatment, and prevention. Ann Intern Med 1988;108:221-37.
91. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-20.
92. Melbye M, Biggar R, Ebbesen P, Neuland C, Goedert J, Faber V. Long-term seropositivity for human T-lymphotrophic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. Ann Intern Med 1986;104:496-500.
93. Friedman-Kien A, Lafleur M, Gendlelr E, Hennessey N, Montagna R, Halbert S. Herpes zoster: a possible early clinical sign of acquired immunodeficiency syndrome in high risk individuals. J Am Acad Dermatol 1986;14:1023-8.
94. Colebunders R, Mann J, Francis H, Bila K, Izaley I, Ilwaya M. Herpes zoster in African patients: a clinical predictor of human immunodeficiency virus infection. J Infect Dis 1988;157:314-8.
95. Verroust F, Lemay D, Laurian Y. High frequency of herpes zoster in young hemophiliacs. N Engl J Med 1987;316:166-7.
96. Van de Perre P, Bakkeers E, Batungwanayo J, Kesteyln P, Lepage P, Nzaramba D. Herpes zoster in African patients: an early manifestation of HIV infection. Scand J Infect Dis 1988;20:277-82.
97. Melbye M, Grossman R, Goedert J, Eyster M, Biggar R. Risk of AIDS after herpes zoster. Lancet 1987;1:728-31.
98. Veenstra J, Krol A, van Praag R, Frissen PH, Schellekens P, Lang J. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995;9:1153-8.
99. van Griensven G, de Vroome E, de Wolf F, Goudsmit J, Roos M, Coutinho R. Risk factors for progression of human immunodeficiency virus (HIV) infection among seroconverted and seropositive homosexual men. Am J Epidemiol 1990;132:203-10.
100. Buchbinder S, Katz M, Hessol N, Liu J, O'Malley P, Underwood R. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-6.
101. McNulty A, Li Y, Radtke U, et al. Herpes zoster and the stage and prognosis of HIV-I infection. Genitourin Med 1997;73:467-70.
102. Moss A, Bacchetti P, Osmond D, Krampf W, Chaisson R, Stites D. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up on the San Francisco General Hospital cohort. BMJ 1988;296:745-50.
103. Morbidity and Mortality Weekly Report. Varicella-related deaths among adults - United States, 1997. Arch Dermatol 1997;133:1059-60.
104. Galil K, Choo PW. The sequelae of herpes zoster. Arch Intern Med 1997;157:1209-13.
105. Schoenlaub P, Grange F, Nasica X. Ocular motor paralysis and complete ptosis in herpes zoster ophthalmicus: two cases. Ann Dermatol Venereol 1997;124:401-3.
106. Choo P, Galil K, Donahue J, Walker A, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med 1997;157:1217-24.
107. Kost R, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med 1996;335:32-42.
108. Tucker ME. Varicella vaccine's benefits outweigh the risks. Skin Allergy News 1997;20.
109. Peterson CL, Mascola L, Chao SM. Children hospitalized for varicella: a prevaccine review. J Pediatr 1996;129:529-36.
110. Prevention CfDCa, prevention of varicella: recommendations of the AICP. MMWR Morbid Mortal Wkly Rep 1996;45:1-32.
111. MMWR. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, July 1996-June 1997. JAMA 1998;279:985-6.
112. McDonnell WM, Askari FK. Immunization. JAMA 1997; 278:2000-7.
113. Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 1997;100:761-6.
114. Ventura A. Varicella vaccination guidelines for adolescents and adults. Am Fam Physician 1997;55:1220-4.
115. Asano Y, Suga S. Experience and reason: twenty year follow up of protective immunity of the Oka live varicella vaccine. Pediatrics 1994;94:524-6.
116. Balfour H, Kelly J, Suarez C. Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 1990;116:633-9.
117. Balfour H, Rotbart H, Feldman S. Acyclovir treatment of varicella in otherwise healthy adolescents. J Pediatr 1992; 120:627-33.
118. Dunkle L, Arvin A, Whitley R. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991;325:1539-44.
119. Lin T-Y, Haung Y-C, Ning H-C, Hsueh C. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997;16:1162-5.
120. Beutner KR, Friedman DJ. Valacyclovir compared to acyclovir for improved therapy for herpes zoster in immuno-competent adults. Antimicrob Agents Chemother 1995;39: 1546-53.
121. Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994;4:241-6.
122. Tyring S, Barbarach R, Nahlik J, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. Ann Intern Med 1995;123:89-96.
123. Tyring S, Belanger R, Bezwoda W, Boon R, Saltzman R. The efficacy and safety of famciclovir (FCV) for the treatment of herpes zoster (HZ) in immunocompromised (IC) patients [poster 243]. Proceedings of the 56th annual meeting of the American Academy of Dermatology; 1998 Mar 2-6; Orlando, Florida. Orlando: The Academy; 1998.
124. Shafran S, Tyring S, Ashton R, et al. Once, twice, or thrice daily famciclovir compared with acyclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. 1998. In press.
125. Wood MJ. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896-900.
126. Whitley RJ, Weiss H. Acyclovir with and without prednisone for the treatment of herpes zoster. Ann Intern Med 1996;125:376-83.
127. Gnann J, Crumpacker C, Lalezari J, Smith J, Tyring S. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Antimicrob Agents Chemother 1998;42:1139-45.
128. Soltz-Szots J, Tyring S, Anderson P, et al. A randomized controlled trial of acyclovir versus netivudine for treatment of herpes zoster. J Antimicrob Chemother 1998;41:549-56.
129. Miller G. Epstein-Barr virus: biology, pathogenesis, and medical aspects. In: Fields B, Knipe D, editors. Virology. New York: Raven Press; 1990. p 1921-58.
130. Schlossberg D. Infectious mononucleosis. New York: Springer-Verlag; 1989.
131. Yen A, Fearneyhough P. EBV-associated Kikuchi's histiocytic necrotizing lymphadenitis with cutaneous manifestations. J Am Acad Dermatol 1997;36:242-6.
132. Straus S, Cohen J, Tosato G, Meier J. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993;118:45-8.
133. Cohen J. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991;70:137-60.
134. Jones J, Shurin S, Abramowsky C, Tubbs R, Sciotto C, Wahl R. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infecions. N Engl J Med 1988;318:733-41.
135. Paul C, Tourneau A, Cayuela J, et al. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dematol 1997;133:867-71.
136. Reference deleted in press.
137. Blatt J. Cutaneous vesicles in congenital cytomegalovirus infection. J Pediatr 1978;92:509.
138. Bhawan J. Vesiculobullous lesions caused by cytomegalovirus infection in an immunocompromised adult. J Am Acad Dermatol 1984;11:743-7.
139. Reference deleted in press.
140. Reference deleted in press.
141. Fenoglio CM. Kaposi's sarcoma following chemotherapy for testicular cancer in a homosexual man: demonstration of cytomegalovirus RNA in sarcoma cells. Hum Pathol 1982; 15:955-9.
142. Reference deleted in press.
143. Sugiura H. Successful treatment of disseminated cutaneous cytomegalic inclusion disease with Hodgkin's disease. J Am Acad Dermatol 1991;24:346-52.
144. Smith KJ. Concurrent epidermal involvement of cytomegalovirus and herpes simplex virus in two HIV-infected patients. J Am Acad Dermatol 1991;25:500-6.
145. Jacobson MA. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome. Ann Intern Med 1988; 108:585-99.
146. Levy JA. Three new human herpesviruses (HHV6, 7, 8). Lancet 1997;349:558-62.
147. Carrigan DG, Dobryski WR. Interstitial pneumonias associated with human herpesvirus-6 infection after marrow transplantation. Lancet 1991;338:147-9.
148. Drobyski WR, Dunne WM. Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow suppressive role for HHV-6 in vivo. J Infect Dis 1993;167:735-9.
149. Chen M, Popesci N. Human herpesvirus 6 infects cervical epithelial cells and transactivates human papillomaaviras gene expression. J Virol 1994;68:1173-8.
150. Leach CT, Newton ER. Human herpesvirus 6 infection of the female genital tract. J Infect Dis 1994;169:1281-3.
151. Yadav M, Chandrashekran A. Frequent detection of human herpesvirus 6 in oral carcinoma. J Natl Cancer Inst 1994;86: 1792-4.
152. Hall CB, Long CE. Human herpesvirus-6 infection in children: a prospective study of complications and reactivation. N Engl J Med 1994;331:432-8.
153. Scheel MM, Rady PL, Tyring SK. Sinus histiocytosis with massive lymphadenopathy: presentation as giant granuloma annulare and detection of human herpes virus 6. J Am Acad Dermatol 1997;37:643-6.
154. Ruzicka T, Kalka K. Papular-purpuric "gloves and socks" syndrome associated with human herpesvirus 6 infection. Arch Dermatol 1998;134:242-4.
155. Ablashi DV, Berneman ZN. Human herpesvirus-7 (HHV-7): current status. Clin Diagn Virol 1995;4:1-13.
156. Drago F, Ranieri E, Malaguti F, Losi E, Rebora A. Human herpesvirus 7 in pityriasis rosea. Lancet 1997;349:1367-8.
157. Rady PL, Kodak E, Yen A, et al. Detection of human herpesvirus-8 DNA in Kaposi's sarcomas from iatrogenically immunosuppressed patients. J Am Acad Dermatol 1998;38: 429-37.
158. Gaspari A, Marchese S, Powell D, Rady P, Tyring S. Identification of HHV-8 DNA in the skin lesions of Kaposi's sarcoma in an immunosuppressed patient with bullous pemphigoid. J Am Acad Dermatol 1997;37:843-7.
159. Burdick AE, Carmichael C, Rady PL, Tyring SK, Badiavas E. Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy. J Am Acad Dermatol 1997;37:648-9.
160. Memar OM, Rady PL, Tyring SK. Human herpesvirus-8: detection of novel herpesvirus-like DNA sequences in Kaposi's sarcoma and other lesions. J Mol Med 1995;73: 603-9.
161. Cesarman E, Chang Y. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-91.
162. Memar O, Rady P, Goldblum R, Yen A, Tyring S. Human herpesvirus 8 DNA sequences in blistering skin from patients with pemphigus. Arch Dermatol 1997;133:1247-51.
163. Martin J, Ganem D, Osmond D, Page-Schafer K, Macrae D, Kedes D. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998;338:948-54.
164. Meadows K, Tyring S, Pavia A, Rallis T. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997;133:987-90.
165. Hicks C, Myers S. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonovir. Clin Infect Dis 1997;24:1023-5.
166. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122-63.
167. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
168. Ho G. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
169. Bosch F, Manos M, Munoz N. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;796-802.
170. Brown D, Fife K. Human papillomavirus infections of the genital tract. Med Clin North Am 1990;74:1455-85.
171. Krebs H-B. Treatment of genital condylomata with topical 5-fluorouracil. Dermatol Clin 1991;9:333-41.
172. Swinehart J, Skinner R, McCarty J, Miller B. Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies. Genitourin Med 1997;73:481-7.
173. Vere Hodge RA. Papillomaviruses. Proceedings of the 10th International Conference on Antiviral Research; 1997 Apr 6-11; Atlanta, Georgia. Atlanta: The Conference; 1997.
174. Snoeck R, Van Rant M, Andrei G. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphate analogue. N Engl J Med 1995;333:943-4.
175. Tyring S, Douglas J, Corey L. A phase I/II study of cidofovir gel for refractory condyloma acuminatum in patients with HIV infection [poster 296]. Proceedings of the 55th annual meeting of the American Acedemy of Dermatology; 1997 Mar 21-26; San Francisco, California. San Francisco: The Academy; 1997.
176. Van Cutsem E, Snowck R, Van Ranst M. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phoshonyl-methoxypropyl) cytosine. J Med Virol 1995;45:230-5.
177. Zabawski E, Sands B, Goetz D, Naylor M. Treatment of verruca vulgaris with topical cidofovir. JAMA 1997;278:1236.
178. Peterson C, Weismann K. Quercetin and kaempherol: an argument against the use of podophyllin. Genitourin Med 1995;72:92-3.
179. Kirby P, Dunne A, King DH, Corey L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990;88:465-9.
180. Greenberg MD, Rutledge LH, Reid R, Berman NR. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991;77:735-9.
181. Beutner KR, Conant MA, Freidman-Kien AE, Illeman M. Patient-applied podofilox for treatment of genital warts. Lancet 1989;1:831-4.
182. Tyring SK, Edwards L, Cherry LC. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998;134:33-8.
183. Vance JC, Bart BJ, Hansen RC, Reichman RC. Intralesional recombinant alfa-2 Interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986;122:272-7.
184. Friedman-Kein AE, Evan LT, Conant M. Natural interferon alfa for treatment of condyloma acuminata. JAMA 1988;259:533-8.
185. Eron SJ, Judson F, Tucker S. Interferon therapy for condyloma acuminata. N Engl J Med 1986;315:1059-64.
186. Edwards L, Ferenczy A, Lawrence E, Baker D. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30.
187. Reichman R, Oakes D, Bonnez W. Treatment of condyloma acuminatum with three different interferons administered intralesionally: a double-blind, placebo-controlled trial. Ann Intern Med 1988;108:675-9.
188. Reiter MJ, Testerman TL, Miller ML, Weeks CE. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 1994;55:234-40.
189. Tyring S, Arany I, Stanely M, Tomai M. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178: 551-5.
190. Harrison C, Jenski L, Voychehovski R. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1988;10:209-24.
191. Harrison C, Miller R, Bernstein D. Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother 1994;38: 2059-64.
192. Sidky Y, Borden E, Weeks C. Inhibition of murine tumour growth by an interferon-inducing imidazoquinolinanine. Cancer Res 1992;52:3528-33.
193. Beutner KR, Spruance-SL, Hougham AJ, Fox TL. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9.
194. Beutner K, Tyring S, Trofatter K, Douglas J. Imiquimod, a patient applied immune response modifier for the treatment of external genital warts. Antimicrobial Agents Chemother 1998;42:789-94.
195. Conant M, Opp K, Gilson R, Shupack J. A vehicle-controlled safety and efficacy trial evaluating 5% imiqimod cream for the treatment of genital/perianal warts in HIV-positive patients [poster 225]. Proceedings of the annual meeting of the American Academy of Dermatology; 1998 Feb 27-Mar 4; Orlando, Florida. Orlando: The Academy; 1998.
196. Ackerman S, Monath T, Budowksy E. Controlled clinical trial of PEN203 in treatment of HPV-associated genital and cutaneous warts [abstract 10983]. Proceedings of the International Congress of Infectious Diseases; 1998 May 15-18; Boston, Massachusetts. Boston: The Congress; 1998.
197. Beutner K. Therapeutic approaches to genital warts. Am J Med 1997;102:28-37.
198. De Villiers E-M. Heterogeneity of the human papillomavirus group. J Virol 1989;63:4898-903.
199. Morbidity and Mortality Weekly Report. Measles - United States, 1997. JAMA 1998;279:1685-6.
200. Morbidity and Mortality Weekly Report. Progress toward elimination of measles from the Americas. JAMA 1998;279:1154-5.
201. Food and Drug Administration. FDA approves new chronic hepatitis C treatment. FDA Med Bull 1998;Summer:5-6.
202. Schwaber M, Zlotogoroski A. Dermatologic manifestations of hepatitis C infection. Int J Dermatol 997;36:251-4.
203. Gross J. Clinician's guide to hepatitis C. Mayo Clin Proc 1998;73:355-61.
204. Hoofnagle J, di Bisceglie A. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.